By Elena Vardon
Partners Group Holding said it will buy a majority stake in antibody research organization FairJourney Biologics.
The Swiss private-equity firm didn't disclose the size of the investment but said that GHO Capital Partners, who it is buying the stake from, will remain a minority stakeholder and that founder Antonio Parada will also keep a significant shareholding.
FairJourney Biologics partners with pharmaceutical and biotechnology companies to develop antibody-based therapies.
According to a report from the Financial Times on Sunday, the deal values FairJourney Biologics at around 900 million euros ($964.4 million).
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
07-01-24 0231ET